Search
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.
Sodium lauryl sulfate
go.drugbank.com/drugs/DB00815ApprovedIt is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity. … SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes.
Categories: Compounds used in a research, industrial, or household settingEvening primrose oil
go.drugbank.com/drugs/DB11358ApprovedNutraceuticalIn its composition it presents some fatty acids such as [DB00132] and [DB13854]. … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]
Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin EProducts: Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA), Nn EVENING PRIMROSE OIL 500MG (with 10% GLA)Dupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalIt was first approved by the FDA in 2017. … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Products: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled SyringePadeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]
Categories: Sensitizers Used in Photodynamic/radiation TherapyTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. … [L41730] TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335]
Categories: Compounds used in a research, industrial, or household settingNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.
Ioxitalamic acid
go.drugbank.com/drugs/DB13444ApprovedWithdrawnUntil the last review in 2015, this drug is still available in the market.[L1113] … [A33006] Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995.
Categories: Compounds used in a research, industrial, or household settingSuccimer
go.drugbank.com/drugs/DB00566ApprovedInvestigationalA mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.
Categories: Compounds used in a research, industrial, or household settingInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalInsulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able … As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood.
Categories: Drugs Used in DiabetesProducts: NovoRapid FlexPen 100U/ml solution for injection in pre-filled pen, RYZODEG® FLEXTOUCH® SOLUTION FOR INJECTION IN PRE-FILLED PEN 100 U/ml